Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFOMalDAR2SC16-MB1
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-DFOMalDAR2SC16-MB1 is an immuno-PET (positron emission tomography) imaging agent designed to target Delta-like protein 3 (DLL3). It consists of the SC16 monoclonal antibody, a humanized IgG1 that binds with high affinity to DLL3, conjugated to the desferrioxamine (DFO) chelator via a maleimide (Mal) linker with a drug-to-antibody ratio (DAR) of 2, and radiolabeled with the positron-emitting isotope Zirconium-89 (89Zr). DLL3 is an atypical Notch ligand that is significantly upregulated on the surface of small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors, while expression in normal tissues is minimal. This tracer facilitates the non-invasive assessment of DLL3 expression, aiding in patient stratification for DLL3-targeted treatments (such as antibody-drug conjugates or T-cell engagers) and monitoring therapeutic efficacy. The "MB1" designation refers to a specific site-specific conjugation methodology or variant used to ensure a homogenous DAR and optimal pharmacokinetic properties.
- Other names
- 89Zr-labeled SC1689Zr-desferrioxamine-SC16
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on 89Zr-DFOMalDAR2SC16-MB1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFOMalDAR2SC16-MB1.